GlaxoSmithKline PLC ADR
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $8,505,898 | $8,547,000 | $7,986,000 | $7,516,000 |
Gross Profit | 5,901,226 | 6,289,000 | 5,821,000 | 5,579,000 |
EBITDA | 1,735,132 | 3,361,000 | 3,230,000 | 3,093,000 |
EBIT | 952,447 | 2,623,000 | 2,071,000 | 2,270,000 |
Net Income | 627,727 | 2,013,000 | 1,443,000 | 1,624,000 |
Net Change In Cash | 8,505,898 | 8,547,000 | 7,986,000 | 7,516,000 |
Free Cash Flow | 1,476,087 | 2,599,208 | 1,463,000 | 697,000 |
Cash | 3,391,029 | 4,437,240 | 4,931,889 | 5,761,908 |
Basic Shares | 2,043,000 | 2,051,000 | 2,055,000 | 2,068,500 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $31,951,117 | $31,376,000 | $30,328,000 | $29,324,000 |
Gross Profit | 23,178,669 | 22,328,000 | 21,763,000 | 19,770,000 |
EBITDA | 11,622,589 | 6,668,000 | 9,083,000 | 8,601,000 |
EBIT | 7,927,382 | 4,117,000 | 6,789,000 | 6,454,000 |
Net Income | 5,590,736 | 2,575,000 | 4,928,000 | 14,956,000 |
Net Change In Cash | 31,951,117 | 31,376,000 | 30,328,000 | 29,324,000 |
Free Cash Flow | 5,824,498 | 3,572,000 | 6,257,522 | 5,145,000 |
Cash | 3,391,029 | 3,693,000 | 3,742,812 | 3,723,000 |
Basic Shares | 2,058,500 | 2,071,000 | 2,055,500 | 2,042,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0.69 |
2025-09-30 | $1.45 |
2025-06-30 | $1.24 |
